Combined Suicide and Cytokine Gene Therapy for Peritoneal Carcinomatosis

[en] BACKGROUND: Gene therapy is a novel approach for the treatment of cancers, and tumours disseminated in the peritoneal cavity are suitable for in situ delivery of a therapeutic gene. AIMS: The efficacy of a therapy combining a suicide gene (herpes simplex virus type I thymidine kinase (HSV-TK)) and cytokine genes was investigated in a model of peritoneal carcinomatosis induced by colon carcinoma cells in syngeneic rats. MATERIAL AND METHODS: Pre-established macroscopic tumours in BDIX rats were treated by intraperitoneal injections of retrovirus producing cells (FLYA13 TK, FLYA13 granulocyte macrophage-colony stimulating factor (GM-CSF), FLYA13 interleukin 12 (IL-12)) and ganciclovir (GCV). RESULTS: TK/GCV treated animals showed a slight increase in survival time (72 days) compared with the control group (63 days) while the association of cytokine and TK/GCV gene therapy resulted in significantly improved survival, with a large proportion of animals remaining tumour free on day 480 (60% and 40% for TK/GCV/GM-CSF and TK/GCV/IL-12 treated animals, respectively). Histological analysis of treated animals showed that the remaining tumour nodes were infiltrated by mononuclear cells but no major differences were observed between the various treatments. Immunohistochemical analysis revealed that lymphoid CD4(+) and CD8(+) T cells as well as macrophages accumulated outside untreated tumour nodes while CD8(+) and CD25(+) activated T cells and macrophages heavily infiltrated the tumours after the different treatments. CONCLUSIONS: Our data indicate that combined suicide and cytokine gene therapy is a powerful approach for the treatment of macroscopic peritoneal carcinomatosis.

Disciplines :

Hematology

Author, co-author :

Lechanteur, Chantal ; Centre Hospitalier Universitaire de Liège - CHU > Hématologie clinique

Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

Princen, Frédéric

Lopez Y Cadenas, Miguel ; Centre Hospitalier Universitaire de Liège - CHU > Génétique

Fillet, Georges ; Université de Liège - ULiège > Département des sciences cliniques > Hématologie - Oncologie médicale

Gielen, Jacques

Merville, Marie-Paule ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale

Bours, Vincent ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Génétique générale et humaine

Language :

English

Title :

Combined Suicide and Cytokine Gene Therapy for Peritoneal Carcinomatosis

Publication date :

September 2000

Journal title :

Gut

ISSN :

0017-5749

eISSN :

1468-3288

Publisher :

BMJ Publishing Group, United Kingdom

Volume :

Issue :

Pages :

343-8

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 31 March 2009

Statistics

Number of views

84 (4 by ULiège)

Number of downloads

160 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

1 Freeman SM, Whartenby KA, Freeman JL, et al. In situ use of suicide genes for cancer therapy. Semin Oncol 1996;23:31-45.
2 Moolten FL, Wells JM, Heyman RA, et al. Lymphoma regression induced by ganciclovir in mice bearing a herpes thymidine kinase transgene. Hum Gene Ther 1990;1:125-34.
3 Lechanteur C, Princen F, Lo Bue S, et al. HSV-1 thymidine kinase gene therapy for colorectal adenocarcinoma-derived peritoneal carcinomatosis. Gene Ther 1997;4:1189-94.
4 Princen F, Lechanteur C, Lopez M, et al. Repeated cycles of retrovirus-mediated HSVtk gene transfer plus ganciclovir increase survival of rats with peritoneal carcinomatosis. Gene Ther 1998;5:1054-60.
5 Barba D, Hardin J, Ray J, et al. Thymidine kinase-mediated killing of rat brain tumors. J Neurosurg 1993;79:729-35.
6 Caruso M, Panis Y, Gagandeep S, et al. Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Prac Nad Acad Sci USA 1993:90:7024-8.
7 Culver KW, Ram Z, Walbridge S, et al. In vivo gene transfer with retroviral vector-producer cells for treatment of experimental brain tumors. Science 1992;256:1550-2.
8 Moolten FL, Wells JM. Curability of tumors bearing herpes thymidine kinase genes transferred by retroviral vectors. J Natl Cancer Inst 1990;82:297-300.
9 Maron A, Gustin T, Le Roux A, et al. Gene therapy of rat C6 glioma using adenovirus-mediated transfer of the herpes simplex virus thymidine kinase gene: long-term follow-up by magnetic resonance imaging. Gene Ther 1996; 3:315-22.
10 Ram Z, Culver KW, Walbridge S, et al. In situ retroviral-mediated gene transfer for treatment of brain tumors in rats. Cancer Res 1993;53:83-8.
11 Sterman DH, Treat J, Litzky A, et al. Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 1998;7:1083-92.
12 Chen C-Y, Chang Y-N, Ryan P, et al. Effect of herpes simplex virus thymidine kinase expression levels on ganciclovir-mediated cytotoxicity and the "bystander effect". Hum Gene Ther 1995;6:1467-76.
13 Freeman SM, Abboud CN, Whartenby KA, et al. The "bystander-effect": tumor regression when a fraction of the tumor mass is genetically modified. Cancer Res 1993;53: 5274-83.
14 Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet 1997;349:2-3.
15 Cavallo F, Signorelli P, Giovarelli M, et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997;89:1049-58.
16 Zitvogel L, Tahara H, Robbins PD, et al. Cancer immunotherapy of established tumors with IL-12. J Immunol 1995;155:1393-403.
17 Bramson JL, Hitt M, Addison CL, et al. Direct intratumoral injection of an adenovirus expressing interleukin-12 induces regression and long-lasting immunity that is associated with highly localized expression of interleukin-12. Hum Gen Ther 1996;7:1995-2002.
18 Brunda MJ, Luistro L, Warrier RR, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993;178:1223-30.
19 Lode HN, Dreier T, Xiang R, et al. Gene therapy with a single chain interleukin 12 fusion protein induces T cell-dependent protective immunity in a syngeneic model of murine neuroblastoma. Proc Natl Acad Sci USA 1998;95:2475-80.
20 Rakhmilevich AL, Turner J, Ford MJ, et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine Tumors. Proc Natl Acad Sci USA 1996; 93:6291-6.
21 Tahara H, Zitvogel L, Storkus WJ, et al. Effective eradication of established murine tumors with IL-12 gene therapy using a polycistronic retroviral vector. J Immunol 1995;154: 6466-74.
22 Qin H, Chatterjee K. Cancer gene therapy using tumor cells infected with recombinant vaccinia virus expressing GM-CSF. Hum Gene Ther 1996;7:1853-60.
23 Yu JS, Burwick JA, Dranoff G, et al. Gene therapy for metastatic brain tumors by vaccination with granulocyte-macrophage colony-stimulating factor-transduced tumor cells. Hum Gene Ther 1997;8:1065-72.
24 Lee C-T, Wu S, Ciernik F, et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther 1997;8:187-93.
25 Dranoff G, Jaffee E, Lazenby A, et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993;90:3539-3543.
26 Cosset F-L, Takeuchi Y, Batttini J-L, et al. High-liter packaging cells producing recombinant retroviruses resistant to human serum. J Virol 1995;69:7430-6.
27 Perrin P, Cassagnau E, Burg C, et al. An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology 1994;107:1697-708.
28 Barba D, Hardin J, Sadelain M, et al. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA 1994;91:4348-52.
29 Vile RG, Nelson JA, Castleden S, et al. Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune system. Cancer Res 1994;54:6228-34.
30 Vile RG, Castleden S, Marshall J, et al. Generation of an anti-tumor immune response in a non-immunogenic tumor: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a TH1-like profile of intratumoral cytokine expression. Int J Cancer 1997;71:267-74.
31 Felzmann T, Ramsey W, Blaese R. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6 or B7-1. Gene Ther 1997;4:1322-9.
32 Gagandeep S, Brew R, Green B, et al. Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". Cancer Gene Ther 1996;3: 83-8.
33 Ramesh R, Marrogi AJ, Munshi A, et al. In vivo analysis of the "bystander effect": a cytokine cascade. Exp Hematol 1996;24:829-38.
34 Bonnekoh B, Greenhalgh DA, Chen S-H, et al. Ex vivo and in vivo adenovirus-mediated gene therapy strategies induce a systemic anti-tumor immune defence in the B16 melanoma model. J Invest Dermatol 1998;110:867-71.
35 Hayashi S, Emi N, Yokoyama I, et al. Inhibition of establishment of hepatic metastasis in mice by combination gene therapy using both herpes simplex virus-thymidine kinase and granulocyte macrophage-colony stimulating factor genes in murine colon cancer. Cancer Gene Ther 1997;4:339-44.
36 Coll J-L, Mesnil M, Lefebvre M-F, et al. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ ganciclovir and IL-2 treatments. Gene Ther 1997;4:1160-6.
37 Chen S, Li Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995;92:2577-81.
38 Chen S-H, Kosai K-I, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res 1996;56:3758-62.
39 Consalvo M, Mullen CA, Modesti A. 5-Fluorocytosine induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol 1995; 154:5302-12.
40 Misawa T, Chiang MH, Pandit L, Gordon EM, Anderson WF, Parekh D, Development of systemic immunologic responses against hepatic metastases during gene therapy for peritoneal carcinomatosis with retroviral Hs-tk and ganciclovir. J Gastrointest Surg 1997;1:527-33.